Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -44.32% is 79% above its 5-year average of -215.47%, near the high end of its 5-year range (-885.13%–-44.32%).
23.22% above its 12-month average of -57.72%.
Reported quarterly return on assets; no daily interpolation. Q3 FY2026 (2026-07-31): -5.36%.
RETURN ON ASSETS (ROA)
-44.32%
RETURN ON ASSETS (ROA) AVG TTM
-57.72%
RETURN ON ASSETS (ROA) AVG 3Y
-286.30%
RETURN ON ASSETS (ROA) AVG 5Y
-215.47%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+23.22%
CURRENT VS 3Y AVG
+84.52%
CURRENT VS 5Y AVG
+79.43%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-23.97%
median of 430 covered companies
CURRENT VS SECTOR MEDIAN
-84.90%
vs the sector median at left
Clearmind Medicine Inc.
Market Cap
$1.11M
Return on Assets (ROA)
-44.32%
TTM Avg
-57.72%
3Y Avg
-286.30%
5Y Avg
-215.47%
Market Cap
$1.14M
Return on Assets (ROA)
-8.84%
TTM Avg
-4.56%
3Y Avg
8.88%
5Y Avg
8.88%
Market Cap
$1.17M
Return on Assets (ROA)
-64.99%
TTM Avg
-31.34%
3Y Avg
-98.36%
5Y Avg
-79.15%
Market Cap
$1.02M
Return on Assets (ROA)
-81.60%
TTM Avg
-1375.39%
3Y Avg
-681.84%
5Y Avg
-547.21%
Market Cap
$888387.00
Return on Assets (ROA)
-160.53%
TTM Avg
-148.83%
3Y Avg
-175.96%
5Y Avg
-127.43%
Market Cap
$885939.00
Return on Assets (ROA)
-1066.69%
TTM Avg
-314.14%
3Y Avg
-238.72%
5Y Avg
-174.21%
Market Cap
$878396.00
Return on Assets (ROA)
-65.16%
TTM Avg
-80.06%
3Y Avg
-104.26%
5Y Avg
-73.53%
Market Cap
$1.36M
Return on Assets (ROA)
-196.18%
TTM Avg
-334.48%
3Y Avg
-197.38%
5Y Avg
-169.68%
Market Cap
$1.37M
Return on Assets (ROA)
-96.27%
TTM Avg
-335.81%
3Y Avg
-263.87%
5Y Avg
-193.48%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Clearmind Medicine Inc. (CMND) | $1.11M | -44.32% | -57.72% | -286.30% | -215.47% |
| Cellyan Biotechnology Co., Ltd (HKPD)vs › | $1.14M | -8.84% | -4.56% | 8.88% | 8.88% |
| IM Cannabis Corp. (IMCC)vs › | $1.17M | -64.99% | -31.34% | -98.36% | -79.15% |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.02M | -81.60% | -1375.39% | -681.84% | -547.21% |
| Decoy Therapeutics Inc. (DCOY)vs › | $888387.00 | -160.53% | -148.83% | -175.96% | -127.43% |
| GlucoTrack, Inc. (GCTK)vs › | $885939.00 | -1066.69% | -314.14% | -238.72% | -174.21% |
| Bone Biologics Corporation (BBLG)vs › | $878396.00 | -65.16% | -80.06% | -104.26% | -73.53% |
| Artelo Biosciences, Inc. (ARTL)vs › | $1.36M | -196.18% | -334.48% | -197.38% | -169.68% |
| Genprex, Inc. (GNPX)vs › | $1.37M | -96.27% | -335.81% | -263.87% | -193.48% |
| Bluejay Diagnostics, Inc. (BJDX)vs › | $787624.00 | -63.04% | -106.06% | -121.33% | -96.21% |
ROA
-44.3%
ROE
-57.9%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-10-31 | -63.41% |
| 2024-10-31 | -52.03% |
| 2023-10-31 | -144.61% |
| 2022-10-31 | -885.13% |
| 2021-10-31 | -87.82% |
| 2020-10-31 | -59.80% |
| 2019-10-31 | -76.88% |
| 2018-10-31 | -105.33% |
| 2017-10-31 | -6.49% |
